

Akseli Hemminki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1006978/publications.pdf>

Version: 2024-02-01

215
papers

10,828
citations

44069

48
h-index

43889

91
g-index

217
all docs

217
docs citations

217
times ranked

10500
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	4.6	686
2	Patterns of metastasis in colon and rectal cancer. <i>Scientific Reports</i> , 2016, 6, 29765.	3.3	652
3	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
4	Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. <i>Nature Medicine</i> , 2011, 17, 96-104.	30.7	348
5	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
6	Metastatic spread in patients with gastric cancer. <i>Oncotarget</i> , 2016, 7, 52307-52316.	1.8	272
7	The epidemiology of metastases in neuroendocrine tumors. <i>International Journal of Cancer</i> , 2016, 139, 2679-2686.	5.1	233
8	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. <i>Molecular Therapy</i> , 2010, 18, 1874-1884.	8.2	201
9	Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. <i>Cancer Research</i> , 2010, 70, 4297-4309.	0.9	197
10	Pancreatic cancer therapy with combined mesothelin-redredirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. <i>JCI Insight</i> , 2018, 3, .	5.0	191
11	Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. <i>Clinical Cancer Research</i> , 2002, 8, 275-80.	7.0	191
12	Gene Transfer to Ovarian Cancer Versus Normal Tissues with Fiber-Modified Adenoviruses. <i>Molecular Therapy</i> , 2002, 5, 695-704.	8.2	170
13	Oncolytic viruses for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 84.	17.0	166
14	Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. <i>Molecular Therapy</i> , 2003, 8, 449-458.	8.2	159
15	Phase I study with ONCOS-102 for the treatment of solid tumors â€“ an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
16	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSFâ€“Coding Oncolytic Adenovirus. <i>Clinical Cancer Research</i> , 2013, 19, 2734-2744.	7.0	150
17	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. <i>Molecular Therapy</i> , 2013, 21, 1212-1223.	8.2	146
18	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. <i>Cancer Research</i> , 2012, 72, 2327-2338.	0.9	144

#	ARTICLE	IF	CITATIONS
19	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1737-1746.	8.2	141
20	Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors. <i>Human Gene Therapy</i> , 2007, 18, 627-641.	2.7	129
21	An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene Expression. <i>Molecular Therapy</i> , 2001, 4, 223-231.	8.2	119
22	Modified adenoviruses for cancer gene therapy. <i>International Journal of Cancer</i> , 2004, 110, 475-480.	5.1	119
23	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. <i>Cancer Research</i> , 2012, 72, 1621-1631.	0.9	117
24	Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA. <i>Journal of Virology</i> , 2008, 82, 11009-11015.	3.4	116
25	Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. <i>Cancer Research</i> , 2002, 62, 1266-70.	0.9	115
26	Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data. <i>Molecular Pharmaceutics</i> , 2011, 8, 12-28.	4.6	106
27	Tissue-Specific Promoters Active in CD44+CD24 ^{low} Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5533-5539.	0.9	100
28	Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 3035-3043.	7.0	97
29	A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. <i>Molecular Therapy</i> , 2003, 7, 163-173.	8.2	93
30	Tissue-specific promoters for cancer gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 683-696.	3.1	91
31	Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 77-86.	4.4	88
32	Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24 ^{low} Cells. <i>Molecular Therapy</i> , 2007, 15, 2088-2093.	8.2	85
33	An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance. <i>Molecular Therapy</i> , 2012, 20, 2076-2086.	8.2	84
34	Integrin targeted oncolytic adenoviruses Ad5 Δ CD24 Δ CRGD and Ad5 Δ CRGD Δ CD24 Δ GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. <i>International Journal of Cancer</i> , 2012, 130, 1937-1947.	5.1	82
35	Oncolytic vaccinia virus for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 595-608.	3.1	78
36	In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus. <i>Journal of the National Cancer Institute</i> , 2002, 94, 741-749.	6.3	75

#	ARTICLE	IF	CITATIONS
37	Adenoviruses for treatment of cancer. <i>Annals of Medicine</i> , 2005, 37, 33-43.	3.8	75
38	Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions. <i>Journal of Virology</i> , 2011, 85, 6390-6402.	3.4	75
39	Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. <i>Cancer Research</i> , 2003, 63, 847-53.	0.9	73
40	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595.	1.9	68
41	An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. <i>Virology</i> , 2004, 324, 103-116.	2.4	67
42	Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. <i>Molecular Therapy</i> , 2012, 20, 1821-1830.	8.2	64
43	Immunological data from cancer patients treated with Ad5/3-E2F- β 24-GMCSF suggests utility for tumor immunotherapy. <i>Oncotarget</i> , 2015, 6, 4467-4481.	1.8	63
44	The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. <i>Journal of Gene Medicine</i> , 2003, 5, 300-310.	2.8	61
45	Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and Serotype Chimerism for Enhanced Selectivity for Ovarian Cancer Cells. <i>Molecular Therapy</i> , 2006, 14, 164-174.	8.2	61
46	Oncolytic Adenoviruses for Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2012, 115, 265-318.	5.0	61
47	Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. <i>Cancer Immunology Research</i> , 2015, 3, 915-925.	3.4	61
48	Concordant and discordant familial cancer: Familial risks, proportions and population impact. <i>International Journal of Cancer</i> , 2017, 140, 1510-1516.	5.1	57
49	Oncolytic Viruses for Induction of Anti-Tumor Immunity. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1750-1760.	1.6	56
50	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. <i>PLoS ONE</i> , 2013, 8, e73964.	2.5	53
51	Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. <i>International Journal of Cancer</i> , 2015, 136, 945-954.	5.1	51
52	Adenoviruses in Oncology. <i>BioDrugs</i> , 2002, 16, 77-87.	4.6	48
53	Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. <i>Oncolimmunology</i> , 2015, 4, e989771.	4.6	47
54	Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 109-121.	4.4	47

#	ARTICLE	IF	CITATIONS
55	Replacement of Adenovirus Type 5 Fiber Shaft Heparan Sulfate Proteoglycan-Binding Domain with RGD for Improved Tumor Infectivity and Targeting. <i>Human Gene Therapy</i> , 2009, 20, 1214-1221.	2.7	46
56	A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses. <i>Journal of Virology</i> , 2012, 86, 6286-6302.	3.4	45
57	Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. , 2020, 8, e000188.		45
58	Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2728-2736.	4.1	44
59	Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. <i>International Journal of Cancer</i> , 2004, 111, 303-309.	5.1	42
60	Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1858-1866.	8.2	42
61	Immunological Effects of a Tumor Necrosis Factor Alpha-“Armed Oncolytic Adenovirus. <i>Human Gene Therapy</i> , 2015, 26, 134-144.	2.7	42
62	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results <i>in vitro</i> , in rodents and in humans. <i>International Journal of Cancer</i> , 2015, 137, 1775-1783.	5.1	41
63	Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3137-3144.	7.0	40
64	Cancer, stem cells, and oncolytic viruses. <i>Annals of Medicine</i> , 2008, 40, 496-505.	3.8	40
65	Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter. <i>Clinical Cancer Research</i> , 2009, 15, 5396-5403.	7.0	39
66	Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 ⁺ T-cell response, prominent infiltration of CD8 ⁺ lymphocytes and Th1 type polarization. <i>Onc Immunology</i> , 2014, 3, e958937.	4.6	39
67	Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. <i>Molecular Therapy</i> , 2018, 26, 2243-2254.	8.2	39
68	Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy. <i>Human Gene Therapy</i> , 2002, 13, 1505-1514.	2.7	38
69	Oncolytic adenovirus Ad5/3-124 and chemotherapy for treatment of orthotopic ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 166-172.	1.4	38
70	Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors. <i>PLoS ONE</i> , 2015, 10, e0131242.	2.5	38
71	Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. <i>Clinical Cancer Research</i> , 2010, 16, 2540-2549.	7.0	37
72	Adenoviral Delivery of Tumor Necrosis Factor- α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. <i>Molecular Therapy</i> , 2016, 24, 1435-1443.	8.2	37

#	ARTICLE	IF	CITATIONS
73	Treatment of prostate cancer with Ad5/31 ^{24hCG} allows non-invasive detection of the magnitude and persistence of virus replication in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 742-751.	4.1	36
74	Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. <i>Journal of Gene Medicine</i> , 2010, 12, 435-445.	2.8	36
75	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. <i>International Journal of Cancer</i> , 2014, 135, 720-730.	5.1	36
76	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. <i>Cancer Immunology Research</i> , 2017, 5, 157-169.	3.4	36
77	Gene Transfer Approaches for Gynecological Diseases. <i>Molecular Therapy</i> , 2006, 14, 154-163.	8.2	35
78	Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 165-174.	5.1	35
79	Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 47-60.	4.4	35
80	Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. <i>Journal of Gene Medicine</i> , 2004, 6, 1333-1342.	2.8	34
81	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment. <i>PLoS ONE</i> , 2017, 12, e0182715.	2.5	34
82	Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 232-239.	2.5	34
83	Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. <i>Cancer</i> , 2006, 107, 1578-1588.	4.1	33
84	Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. <i>Molecular Therapy</i> , 2012, 20, 221-229.	8.2	33
85	Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. <i>International Journal of Cancer</i> , 2009, 125, 2441-2449.	5.1	32
86	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. <i>Acta Oncologica</i> , 2010, 49, 120-122.	1.8	32
87	Expression of DAL by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16002.	4.4	32
88	Oncolytic adenoviruses. <i>Oncolmmunology</i> , 2012, 1, 979-981.	4.6	31
89	Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2259-2269.	4.1	31
90	Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. <i>Journal of Gene Medicine</i> , 2009, 11, 966-977.	2.8	30

#	ARTICLE	IF	CITATIONS
91	Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. <i>Journal of Gene Medicine</i> , 2011, 13, 253-261.	2.8	30
92	Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. <i>Journal of Gene Medicine</i> , 2007, 9, 3-9.	2.8	29
93	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1078057.	4.6	29
94	Virotherapy as An Approach Against Cancer Stem Cells. <i>Current Gene Therapy</i> , 2008, 8, 88-96.	2.0	28
95	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1323-1332.	8.2	28
96	CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. <i>Oncolimmunology</i> , 2018, 7, e1490856.	4.6	28
97	Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. <i>Cancer Gene Therapy</i> , 2003, 10, 377-387.	4.6	26
98	Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. <i>Cancer Gene Therapy</i> , 2003, 10, 583-588.	4.6	26
99	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2016, 24, 175-183.	8.2	26
100	Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 443-455.	3.1	26
101	TNF α and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. <i>Cells</i> , 2020, 9, 798.	4.1	26
102	Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus. <i>PLoS ONE</i> , 2010, 5, e13859.	2.5	25
103	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. <i>European Journal of Cancer</i> , 2010, 46, 625-635.	2.8	25
104	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. <i>Oncolimmunology</i> , 2017, 6, e1265717.	4.6	25
105	[¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer. <i>Human Gene Therapy</i> , 2013, 24, 1029-1041.	2.7	23
106	Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. <i>Molecular Therapy</i> , 2015, 23, 1641-1652.	8.2	23
107	GMCSF-armed vaccinia virus induces an antitumor immune response. <i>International Journal of Cancer</i> , 2015, 136, 1065-1072.	5.1	23
108	Risk of other Cancers in Families with Melanoma: Novel Familial Links. <i>Scientific Reports</i> , 2017, 7, 42601.	3.3	23

#	ARTICLE	IF	CITATIONS
109	Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. <i>Journal of Gene Medicine</i> , 2004, 6, 1281-1289.	2.8	22
110	Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction. <i>International Journal of Cancer</i> , 2018, 143, 2449-2457.	5.1	22
111	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. <i>Oncolmmunology</i> , 2020, 9, 1761229.	4.6	22
112	Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. <i>Frontiers in Immunology</i> , 2021, 12, 674400.	4.8	22
113	The flt-1 promoter for transcriptional targeting of teratocarcinoma. <i>Cancer Research</i> , 2002, 62, 1271-4.	0.9	22
114	SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and 131I. <i>PLoS ONE</i> , 2012, 7, e32871.	2.5	21
115	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF α Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. <i>Journal of Immunotherapy</i> , 2016, 39, 343-354.	2.4	21
116	Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. <i>Cells</i> , 2021, 10, 246.	4.1	21
117	Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3- β 24-hNIS. <i>Molecular Therapy</i> , 2011, 19, 629-631.	8.2	20
118	Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. <i>International Journal of Cancer</i> , 2017, 141, 1458-1468.	5.1	20
119	Familial Risks and Proportions Describing Population Landscape of Familial Cancer. <i>Cancers</i> , 2021, 13, 4385.	3.7	20
120	Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. <i>Oncolmmunology</i> , 2022, 11, .	4.6	20
121	A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3- β 24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients. <i>Human Gene Therapy</i> , 2011, 22, 821-828.	2.7	19
122	Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma. <i>Journal of Virology</i> , 2013, 87, 2363-2366.	3.4	19
123	Oncolytic Virotherapy Trials Letter. <i>Clinical Cancer Research</i> , 2013, 19, 4541-4542.	7.0	19
124	Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14008.	4.4	19
125	Familial associations of female breast cancer with other cancers. <i>International Journal of Cancer</i> , 2017, 141, 2253-2259.	5.1	19
126	Familial Associations Between Prostate Cancer and Other Cancers. <i>European Urology</i> , 2017, 71, 162-165.	1.9	19

#	ARTICLE	IF	CITATIONS
127	A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. <i>International Journal of Molecular Medicine</i> , 2006, 18, 751-9.	4.0	18
128	Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver. <i>Human Gene Therapy</i> , 2009, 20, 611-620.	2.7	17
129	Serotype Chimeric Human Adenoviruses for Cancer GeneTherapy. <i>Viruses</i> , 2010, 2, 2196-2212.	3.3	17
130	In vivoandin vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. <i>Annals of Medicine</i> , 2011, 43, 151-163.	3.8	17
131	Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles. <i>BMC Veterinary Research</i> , 2015, 11, 170.	1.9	17
132	Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting. <i>Oncolmmunology</i> , 2016, 5, e1136046.	4.6	17
133	Gene therapy of gynaecological diseases. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1347-1361.	3.1	16
134	Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. <i>Cells</i> , 2021, 10, 978.	4.1	16
135	Survival in colon and rectal cancers in Finland and Sweden through 50 years. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000644.	2.7	16
136	Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 794251.	4.8	16
137	Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. <i>Gynecologic Oncology</i> , 2005, 96, 341-348.	1.4	15
138	Second primary cancers in nonâ€Hodgkin lymphoma: Family history and survival. <i>International Journal of Cancer</i> , 2020, 146, 970-976.	5.1	15
139	Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. <i>Cancer Gene Therapy</i> , 2021, 28, 442-454.	4.6	15
140	Caseâ€Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. <i>Molecular Therapy</i> , 2015, 23, 321-329.	8.2	14
141	Location of metastases in cancer of unknown primary are not random and signal familial clustering. <i>Scientific Reports</i> , 2016, 6, 22891.	3.3	14
142	Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. <i>Lancet Haematology</i> ,the, 2018, 5, e368-e377.	4.6	14
143	Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. <i>Oncolmmunology</i> , 2022, 11, 2028960.	4.6	14
144	Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 3036.	2.8	13

#	ARTICLE	IF	CITATIONS
145	Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 193.	4.4	13
146	In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. <i>International Journal of Cancer</i> , 2014, 134, 2878-2890.	5.1	13
147	Oncolytic Immunotherapy: Where Are We Clinically?. <i>Scientifica</i> , 2014, 2014, 1-7.	1.7	13
148	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. <i>Current Cancer Drug Targets</i> , 2018, 18, 124-138.	1.6	13
149	Second primary cancer after female breast cancer: Familial risks and cause of death. <i>Cancer Medicine</i> , 2019, 8, 400-407.	2.8	13
150	Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. <i>Human Gene Therapy</i> , 2021, 32, 192-202.	2.7	13
151	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. <i>PLoS ONE</i> , 2021, 16, e0253236.	2.5	13
152	Adenovirus Armed With TNF α and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. <i>Frontiers in Immunology</i> , 2021, 12, 706517.	4.8	13
153	Common cancers share familial susceptibility: implications for cancer genetics and counselling. <i>Journal of Medical Genetics</i> , 2017, 54, 248-253.	3.2	12
154	Familial Risks and Mortality in Second Primary Cancers in Melanoma. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky068.	2.9	12
155	Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses. <i>PLoS ONE</i> , 2008, 3, e2917.	2.5	11
156	Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14002.	4.4	11
157	T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses. <i>Molecular Therapy</i> , 2015, 23, 964-973.	8.2	11
158	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.4	11
159	Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. <i>BMC Cancer</i> , 2021, 21, 1189.	2.6	11
160	Effects of capsid ϵ -modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. <i>International Journal of Cancer</i> , 2012, 131, 253-263.	5.1	10
161	Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. <i>Oncotarget</i> , 2018, 9, 6320-6335.	1.8	10
162	Oncolytic adenovirus decreases the proportion of TIM-3 ⁺ subset of tumor-infiltrating CD8 ⁺ T cells with correlation to improved survival in patients with cancer. , 2022, 10, e003490.		10

#	ARTICLE	IF	CITATIONS
163	Genetics of gallbladder cancer. <i>Lancet Oncology</i> , The, 2017, 18, e296.	10.7	9
164	Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition. <i>Methods in Enzymology</i> , 2020, 635, 205-230.	1.0	9
165	Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor. <i>Cancer Medicine</i> , 2020, 9, 8258-8265.	2.8	9
166	Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. <i>European Journal of Cancer Prevention</i> , 2022, 31, 228-234.	1.3	9
167	Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer. <i>Clinical Epidemiology</i> , 2021, Volume 13, 515-525.	3.0	9
168	Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment. <i>BMC Cancer</i> , 2022, 22, 456.	2.6	9
169	Treatment of Chemotherapy-Refractory Cancer in the Advanced Therapy Access Program. <i>Molecular Therapy</i> , 2012, 20, 1654-1655.	8.2	8
170	Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism. <i>PLoS ONE</i> , 2013, 8, e60032.	2.5	8
171	Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14006.	4.4	8
172	Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 41-50.	4.4	8
173	Constitutively active GSK3 ^{Î²} as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. <i>Oncolimmunology</i> , 2019, 8, e1631119.	4.6	8
174	A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy. <i>Acta Oncologica</i> , 2012, 51, 130-133.	1.8	7
175	Familial associations of male breast cancer with other cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 897-902.	2.5	7
176	Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients. <i>Blood Cancer Journal</i> , 2019, 9, 40.	6.2	7
177	Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms?. <i>Journal of Investigative Dermatology</i> , 2020, 140, 48-55.e1.	0.7	7
178	Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. <i>Human Gene Therapy</i> , 2021, 32, 178-191.	2.7	7
179	Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor. <i>BMC Cancer</i> , 2021, 21, 604.	2.6	7
180	Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast. <i>International Journal of Cancer</i> , 2022, 151, 200-208.	5.1	7

#	ARTICLE	IF	CITATIONS
181	Familial Associations of Colorectal Cancer with Other Cancers. <i>Scientific Reports</i> , 2017, 7, 5243.	3.3	6
182	Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. <i>Clinical Epidemiology</i> , 2021, Volume 13, 683-691.	3.0	6
183	Radiation-Induced Upregulation of Gene Expression From Adenoviral Vectors Mediated by DNA Damage Repair and Regulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 376-384.	0.8	5
184	Multiple myeloma: family history and mortality in second primary cancers. <i>Blood Cancer Journal</i> , 2018, 8, 75.	6.2	5
185	Familial Associations of Colon and Rectal Cancers With Other Cancers. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 189-195.	1.3	5
186	Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas—Long-Term Follow Up. <i>Frontiers in Veterinary Science</i> , 2021, 8, 695222.	2.2	5
187	Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country. <i>Cancers</i> , 2022, 14, 1938.	3.7	5
188	A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5 Δ 24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. <i>International Journal of Molecular Medicine</i> , 2006, 18, 751.	4.0	4
189	Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. <i>Molecular Pharmaceutics</i> , 2011, 8, 93-103.	4.6	4
190	Collection and Use of Family History in Oncology Clinics. <i>Journal of Clinical Oncology</i> , 2014, 32, 3344-3345.	1.6	4
191	Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells. <i>PLoS ONE</i> , 2015, 10, e0120496.	2.5	4
192	Incidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues. <i>Clinical Epidemiology</i> , 2020, Volume 12, 857-864.	3.0	4
193	Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. <i>PLoS ONE</i> , 2022, 17, e0261124.	2.5	4
194	Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?. <i>International Journal of Cancer</i> , 2022, 151, 510-517.	5.1	4
195	The cyclooxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3' untranslated region destabilization element can increase specificity. <i>Journal of Gene Medicine</i> , 2008, 10, 744-753.	2.8	3
196	Oncolytic adenovirus research and applications. <i>Future Virology</i> , 2010, 5, 745-761.	1.8	3
197	Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1201-1209.	0.8	3
198	Adenoviruses with an α 5 β 1 integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases. <i>Journal of Translational Medicine</i> , 2010, 8, 80.	4.4	3

#	ARTICLE	IF	CITATIONS
199	Portrait of a Leader in Immunotherapeutics. Human Vaccines and Immunotherapeutics, 2012, 8, 1018-1021.	3.3	3
200	Other cancers in lung cancer families are overwhelmingly smoking-related cancers. ERJ Open Research, 2017, 3, 00006-2017.	2.6	3
201	Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. Human Gene Therapy, 2019, 30, 740-752.	2.7	3
202	Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example. Hereditary Cancer in Clinical Practice, 2020, 18, 15.	1.5	3
203	<p>Second Primary Cancers in Melanoma Patients Critically Shorten Survival</p>. Clinical Epidemiology, 2020, Volume 12, 105-112.	3.0	3
204	Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study. Pigment Cell and Melanoma Research, 2020, 33, 625-632.	3.3	3
205	Types of second primary cancer influence overall survival in cutaneous melanoma. BMC Cancer, 2021, 21, 1123.	2.6	3
206	Cancer Predisposition Genes in Cancer-Free Families. Cancers, 2020, 12, 2770.	3.7	2
207	Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.. Journal of Clinical Oncology, 2014, 32, 23-23.	1.6	2
208	Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5. PLoS ONE, 2010, 5, e13103.	2.5	2
209	TILT Biotherapeutics. Human Vaccines and Immunotherapeutics, 2017, 13, 970-971.	3.3	1
210	Tissue-specific promoters for cancer gene therapy. Expert Opinion on Biological Therapy, 2004, 4, 683-696.	3.1	1
211	First-in-human clinical trial of an oncolytic adenovirus armed with TNF α and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2022, 40, TPS9590-TPS9590.	1.6	1
212	Oncolytic Adenoviruses in the Treatment of Cancer in Humans. , 2014, , 153-170.		0
213	Oncolytic Viruses for Treatment of Cancer. , 2008, , .		0
214	CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.. Journal of Clinical Oncology, 2012, 30, e13035-e13035.	1.6	0
215	Oncolytic Viruses for Treatment of Cancer. , 2015, , 185-200.		0